Extracellular Vesicles from Different Sources of Mesenchymal Stromal Cells Have Distinct Effects on Lung and Distal Organs in Experimental Sepsis

The effects of the administration of mesenchymal stromal cells (MSC) may vary according to the source. We hypothesized that MSC-derived extracellular vesicles (EVs) obtained from bone marrow (BM), adipose (AD), or lung (L) tissues may also lead to different effects in sepsis. We profiled the proteome from EVs as a first step toward understanding their mechanisms of action. Polymicrobial sepsis was induced in C57BL/6 mice by cecal ligation and puncture (SEPSIS) and SHAM (control) animals only underwent laparotomy. Twenty-four hours after surgery, animals in the SEPSIS group were randomized to receive saline or 3 × 106 MSC-derived EVs from BM, AD, or L. The diffuse alveolar damage was decreased with EVs from all three sources. In kidneys, BM-, AD-, and L-EVs reduced edema and expression of interleukin-18. Kidney injury molecule-1 expression decreased only in BM- and L-EVs groups. In the liver, only BM-EVs reduced congestion and cell infiltration. The size and number of EVs from different sources were not different, but the proteome of the EVs differed. BM-EVs were enriched for anti-inflammatory proteins compared with AD-EVs and L-EVs. In conclusion, BM-EVs were associated with less organ damage compared with the other sources of EVs, which may be related to differences detected in their proteome.

[1]  S. Mandacaru,et al.  Proteomics profile of mesenchymal stromal cells and extracellular vesicles in normoxic and hypoxic conditions. , 2022, Cytotherapy.

[2]  C. Sprung,et al.  Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 , 2021, Intensive Care Medicine.

[3]  P. Rocco,et al.  Cell-Free Therapies: Novel Approaches for COVID-19 , 2020, Frontiers in Immunology.

[4]  Ping Wang,et al.  Exosomes in Sepsis , 2020, Frontiers in Immunology.

[5]  Anna Lemańska-Perek,et al.  Plasma and Cellular Forms of Fibronectin as Prognostic Markers in Sepsis , 2020, Mediators of inflammation.

[6]  Ulrich Dirnagl,et al.  The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.

[7]  V. Nobre,et al.  Acute kidney injury biomarkers in the critically ill. , 2020, Clinica chimica acta; international journal of clinical chemistry.

[8]  Zina M. Ibrahim,et al.  On classifying sepsis heterogeneity in the ICU: insight using machine learning , 2019, J. Am. Medical Informatics Assoc..

[9]  K. Tarte,et al.  Integrated transcriptomic, phenotypic, and functional study reveals tissue‐specific immune properties of mesenchymal stromal cells , 2020, Stem cells.

[10]  G. Victorino,et al.  Protective effect of phosphatidylserine blockade in sepsis induced organ dysfunction. , 2019, Surgery.

[11]  M. Hallek,et al.  Extracellular vesicle measurements with nanoparticle tracking analysis – An accuracy and repeatability comparison between NanoSight NS300 and ZetaView , 2019, Journal of extracellular vesicles.

[12]  S. Lim,et al.  Proteomic Signature of Mesenchymal Stromal Cell‐Derived Small Extracellular Vesicles , 2019, Proteomics.

[13]  Martin Eisenacher,et al.  The PRIDE database and related tools and resources in 2019: improving support for quantification data , 2018, Nucleic Acids Res..

[14]  Y. Kaneda,et al.  Chromatin accessibility identifies diversity in mesenchymal stem cells from different tissue origins , 2018, Scientific Reports.

[15]  Jing Xu,et al.  Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines , 2018, Journal of Extracellular Vesicles.

[16]  R. Minghim,et al.  Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer , 2018, Nature Communications.

[17]  J. Fox,et al.  Combining discovery and targeted proteomics reveals a prognostic signature in oral cancer , 2018, Nature Communications.

[18]  M. Singer,et al.  Minimum Quality Threshold in Pre-Clinical Sepsis Studies (Mqtipss): An International Expert Consensus Initiative for Improvement of Animal Modeling in Sepsis , 2018, Shock.

[19]  M. Ghahremani,et al.  Mesenchymal stem cell-derived extracellular vesicles: novel frontiers in regenerative medicine , 2018, Stem Cell Research & Therapy.

[20]  C. D. dos Santos,et al.  Strategies to improve the therapeutic effects of mesenchymal stromal cells in respiratory diseases , 2018, Stem Cell Research & Therapy.

[21]  J. Marshall,et al.  Cellular Immunotherapy for Septic Shock. A Phase I Clinical Trial , 2017, American journal of respiratory and critical care medicine.

[22]  J. Laffey,et al.  Stem Cell–based Therapies for Sepsis , 2017, Anesthesiology.

[23]  L. Reppel,et al.  Mesenchymal Stromal/Stem Cells: A New Treatment For Sepsis And Septic Shock? , 2017 .

[24]  M. Martins,et al.  Human adipose tissue mesenchymal stromal cells and their extracellular vesicles act differentially on lung mechanics and inflammation in experimental allergic asthma , 2017, Stem Cell Research & Therapy.

[25]  B. Diaz,et al.  Bone Marrow, Adipose, and Lung Tissue‐Derived Murine Mesenchymal Stromal Cells Release Different Mediators and Differentially Affect Airway and Lung Parenchyma in Experimental Asthma , 2017, Stem cells translational medicine.

[26]  M. Matthay,et al.  Mesenchymal Stem (Stromal) Cells: Biology and Preclinical Evidence for Therapeutic Potential for Organ Dysfunction following Trauma or Sepsis , 2016 .

[27]  J. Marshall,et al.  Evaluating mesenchymal stem cell therapy for sepsis with preclinical meta-analyses prior to initiating a first-in-human trial , 2016, eLife.

[28]  Marco Y. Hein,et al.  The Perseus computational platform for comprehensive analysis of (prote)omics data , 2016, Nature Methods.

[29]  P. Pelosi,et al.  Comparison of different degrees of variability in tidal volume to prevent deterioration of respiratory system elastance in experimental acute lung inflammation. , 2016, British journal of anaesthesia.

[30]  P. Bozza,et al.  Omega-9 Oleic Acid Induces Fatty Acid Oxidation and Decreases Organ Dysfunction and Mortality in Experimental Sepsis , 2016, PloS one.

[31]  P. Rocco,et al.  Extracellular vesicles derived from mesenchymal stromal cells: a therapeutic option in respiratory diseases? , 2016, Stem Cell Research & Therapy.

[32]  P. Pelosi,et al.  Respiratory and Systemic Effects of LASSBio596 Plus Surfactant in Experimental Acute Respiratory Distress Syndrome , 2016, Cellular Physiology and Biochemistry.

[33]  D. Angus,et al.  Assessment of Global Incidence and Mortality of Hospital-treated Sepsis. Current Estimates and Limitations. , 2016, American journal of respiratory and critical care medicine.

[34]  Y. Tsai,et al.  An Increase in CD3+CD4+CD25+ Regulatory T Cells after Administration of Umbilical Cord-Derived Mesenchymal Stem Cells during Sepsis , 2014, PloS one.

[35]  D. Prough,et al.  Human mesenchymal stem cells reduce the severity of acute lung injury in a sheep model of bacterial pneumonia , 2014, Thorax.

[36]  R. Sacco,et al.  Efficacy and Dose-Dependent Safety of Intra-Arterial Delivery of Mesenchymal Stem Cells in a Rodent Stroke Model , 2014, PloS one.

[37]  T. van der Poll,et al.  Host innate immune responses to sepsis , 2013, Virulence.

[38]  Cheuk-Kwan Sun,et al.  Impact of apoptotic adipose-derived mesenchymal stem cells on attenuating organ damage and reducing mortality in Rat sepsis syndrome induced by cecal puncture and ligation , 2012, Journal of Translational Medicine.

[39]  E. Chernykh,et al.  Multiplex Analysis of Cytokines, Chemokines, Growth Factors, MMP-9 and TIMP-1 Produced by Human Bone Marrow, Adipose Tissue, and Placental Mesenchymal Stromal Cells , 2011, Bulletin of Experimental Biology and Medicine.

[40]  M. Mann,et al.  Andromeda: a peptide search engine integrated into the MaxQuant environment. , 2011, Journal of proteome research.

[41]  Arthur S Slutsky,et al.  Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis. , 2010, American journal of respiratory and critical care medicine.

[42]  Krisztián Németh,et al.  Bone marrow stromal cells attenuate sepsis via prostaglandin E2–dependent reprogramming of host macrophages to increase their interleukin-10 production , 2009, Nature Medicine.

[43]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[44]  D. Rittirsch,et al.  Immunodesign of experimental sepsis by cecal ligation and puncture , 2008, Nature Protocols.

[45]  Christine E. Becker,et al.  Inflammasomes in inflammatory disorders: the role of TLRs and their interactions with NLRs , 2007, Seminars in Immunopathology.

[46]  A. Sher,et al.  Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis. , 2006, Kidney international.

[47]  D. Prockop,et al.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. , 2006, Cytotherapy.

[48]  M. Sitkovsky,et al.  Model organisms: Animal Models of sepsis: setting the stage , 2005, Nature Reviews Drug Discovery.

[49]  J. Prieto Prieto,et al.  Plasma fibronectin as a marker of sepsis. , 2004, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[50]  J. Renauld,et al.  IL-9 Protects Mice from Gram-Negative Bacterial Shock: Suppression of TNF-α, IL-12, and IFN-γ, and Induction of IL-10 , 2000, The Journal of Immunology.

[51]  A. Vaheri,et al.  Cross-linking of a major fibroblast surface-associated glycoprotein (fibronectin) catalyzed by blood coagulation factor XIII , 1976, Cell.